Cargando…
Lack of clinical efficacy of imatinib in metastatic melanoma
This two-centre phase-II trial aimed at investigating the efficacy of imatinib in metastasised melanoma patients in correlation to the tumour expression profile of the imatinib targets c-kit and platelet-derived growth factor receptor (PDGF-R). The primary study end point was objective response acco...
Autores principales: | Ugurel, S, Hildenbrand, R, Zimpfer, A, La Rosée, P, Paschka, P, Sucker, A, Keikavoussi, P, Becker, J C, Rittgen, W, Hochhaus, A, Schadendorf, D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362005/ https://www.ncbi.nlm.nih.gov/pubmed/15846297 http://dx.doi.org/10.1038/sj.bjc.6602529 |
Ejemplares similares
-
Dose-dependent severe cutaneous reactions to imatinib
por: Ugurel, S, et al.
Publicado: (2003) -
Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008) -
B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
por: Ugurel, Selma, et al.
Publicado: (2007) -
STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients
por: Schrama, David, et al.
Publicado: (2014) -
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma
por: Willmes, Christoph, et al.
Publicado: (2016)